AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD

Akari Therapeutics PLC is a clinical-stage biopharmaceutical company that specializes in the development of treatments for rare and orphan diseases. The company is based in London, England and was founded in 2004.

Akari's primary product is nomacopan, a first-in-class complement inhibitor that is designed to treat a range of inflammatory and orphan diseases. Nomacopan works by blocking the C5 and LTB4 pathways of the complement system, which can help to reduce inflammation and prevent tissue damage.

One of the key strengths of Akari is their focus on rare and orphan diseases. The company is committed to developing innovative therapies that can improve the lives of patients with these often-neglected conditions. This focus has allowed Akari to become a trusted partner in the healthcare industry and has helped to build strong relationships with patients, healthcare providers, and other stakeholders.

In addition to their focus on rare and orphan diseases, Akari also places a strong emphasis on research and development. The company invests heavily in R&D, with a focus on developing new therapies and solutions that can address unmet medical needs in the rare disease space. This approach has allowed Akari to stay at the forefront of the rapidly-evolving biopharmaceutical industry.

Financially, Akari has a strong track record of growth and investment. The company has received funding from a variety of sources, including venture capital firms and government grants. As of September 2021, the company had a market capitalization of approximately $80 million.

Akari's American Depository Receipts (ADRs) are listed on the NASDAQ stock exchange, with each ADR representing 100 ordinary shares. However, it is important to note that ADRs do not necessarily have the same rights and privileges as ordinary shares.

Akari Therapeutics PLC is a clinical-stage biopharmaceutical company that is focused on the development of treatments for rare and orphan diseases. The company's focus on rare diseases, commitment to research and development, and strong financial performance make them an attractive partner for healthcare providers, patients, and investors seeking exposure to the biopharmaceutical industry. With their extensive experience and investment in R&D, Akari is well-positioned to continue to develop innovative solutions that can improve the lives of patients with rare and orphan diseases.

YES YOU CAN GO

AXIOM YOU ART